Sequence-Based Prediction for Vaccine Strain Selection and Identification of Antigenic Variability in Foot-and-Mouth Disease Virus
Richard Reeve,
Belinda Blignaut,
Jan J Esterhuysen,
Pamela Opperman,
Louise Matthews,
Elizabeth E Fry,
Tjaart A P de Beer,
Jacques Theron,
Elizabeth Rieder,
Wilna Vosloo,
Hester G O'Neill,
Daniel T Haydon and
Francois F Maree
PLOS Computational Biology, 2010, vol. 6, issue 12, 1-13
Abstract:
Identifying when past exposure to an infectious disease will protect against newly emerging strains is central to understanding the spread and the severity of epidemics, but the prediction of viral cross-protection remains an important unsolved problem. For foot-and-mouth disease virus (FMDV) research in particular, improved methods for predicting this cross-protection are critical for predicting the severity of outbreaks within endemic settings where multiple serotypes and subtypes commonly co-circulate, as well as for deciding whether appropriate vaccine(s) exist and how much they could mitigate the effects of any outbreak. To identify antigenic relationships and their predictors, we used linear mixed effects models to account for variation in pairwise cross-neutralization titres using only viral sequences and structural data. We identified those substitutions in surface-exposed structural proteins that are correlates of loss of cross-reactivity. These allowed prediction of both the best vaccine match for any single virus and the breadth of coverage of new vaccine candidates from their capsid sequences as effectively as or better than serology. Sub-sequences chosen by the model-building process all contained sites that are known epitopes on other serotypes. Furthermore, for the SAT1 serotype, for which epitopes have never previously been identified, we provide strong evidence – by controlling for phylogenetic structure – for the presence of three epitopes across a panel of viruses and quantify the relative significance of some individual residues in determining cross-neutralization. Identifying and quantifying the importance of sites that predict viral strain cross-reactivity not just for single viruses but across entire serotypes can help in the design of vaccines with better targeting and broader coverage. These techniques can be generalized to any infectious agents where cross-reactivity assays have been carried out. As the parameterization uses pre-existing datasets, this approach quickly and cheaply increases both our understanding of antigenic relationships and our power to control disease.Author Summary: New strains of viruses arise continually. Consequently, predicting when past exposure to closely related strains will protect against infection by novel strains is central to understanding the dynamics of a broad range of the world's most important infectious diseases. While previous research has developed valuable tools for describing the observed antigenic landscapes, our ability to predict cross-protection between different viral strains depends almost entirely on cumbersome and expensive live animal work, often restricted to model species rather than the natural host. The development of computer-based approaches to the estimation of cross-protection from viral sequence data would be hugely valuable, and our study represents a significant step towards this research goal.
Date: 2010
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)
Downloads: (external link)
https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1001027 (text/html)
https://journals.plos.org/ploscompbiol/article/fil ... 01027&type=printable (application/pdf)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:plo:pcbi00:1001027
DOI: 10.1371/journal.pcbi.1001027
Access Statistics for this article
More articles in PLOS Computational Biology from Public Library of Science
Bibliographic data for series maintained by ploscompbiol ().